Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

September 3, 2026Posted inBiotechnology

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.

Post navigation

Previous Post
Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’
Next Post
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

Recent Posts

  • The Aging Proteome: Clocks, Cohorts, and Clinical Trials
  • Modeling Reveals How Silica Gold Nanoparticles Reshape Optical Energy and Fields
  • Intravenous Iron Formulations Spur Divergent Muscle Recovery in Iron Deficiency Anaemia
  • SAR and optical data fuse in dynamic graph network to classify sea ice with 96.69% accuracy
  • Grid access cuts solar adoption odds in Cameroon, study finds

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top